Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling
Yueyang Zhang(Guangdong Pharmaceutical University), Xiaojuan Li(Second People Hospital of Hunan), Yiyuan Wang(Southern Medical University), Binhua Zou(Southern Medical University), Hua Zhou(Macau University of Science and Technology), Liang Liu(Hebei Medical University), Jianbing Su(Guangdong Pharmaceutical University), Yanhui Tan(Guangxi Normal University), Lei Tao(East China Normal University), Jialan Xu(Guangdong Pharmaceutical University)
Cited by 39
Related Papers
Oral Hydrogel Microbeads-Mediated In Situ Synthesis of Selenoproteins for Regulating Intestinal Immunity and Microbiota
|Journal of the American Chemical Society|2023|177
Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy
|Acta Pharmaceutica Sinica B|2021|158
Self-targeting visualizable hyaluronate nanogel for synchronized intracellular release of doxorubicin and cisplatin in combating multidrug-resistant breast cancer
|Nano Research|2020|145
Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4/TRAF6 and PLCγ1-Ca2+-NFATc1 signaling pathway
|Acta Pharmacologica Sinica|2019|120
Delivery of triptolide with reduction-sensitive polymer nanoparticles for liver cancer therapy on patient-derived xenografts models
|Chinese Chemical Letters|2020|97